| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BDKRB2 |
| Uniprot No | P30411 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-60aa |
| 氨基酸序列 | MFSPWKISMFLSVREDSVPTTASFSADMLNVTLQGPTLNGTFAQSKCPQV EWLGWLNTIQ |
| 预测分子量 | 32 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BDKRB2(缓激肽受体B2)重组蛋白的3篇代表性文献的模拟示例(注：以下内容为示例，非真实文献，仅供格式参考)：
---
1. **文献名称**: "Structural characterization of recombinant human B2 bradykinin receptor"
**作者**: Smith J, et al.
**摘要**: 通过哺乳动物表达系统重组表达并纯化人源BDKRB2蛋白，利用X射线晶体学解析其三维结构，揭示了缓激肽结合口袋的关键氨基酸残基，为靶向药物设计提供结构基础。
---
2. **文献名称**: "Functional analysis of BDKRB2 in inflammatory response using recombinant protein"
**作者**: Lee H, et al.
**摘要**: 构建BDKRB2重组蛋白体外模型，证明其激活后可触发NF-κB信号通路，促进炎症因子IL-6和TNF-α释放，提示其在炎症性疾病中的潜在调控作用。
---
3. **文献名称**: "Recombinant BDKRB2 as a therapeutic target in hereditary angioedema"
**作者**: Garcia-Ruiz C, et al.
**摘要**: 利用重组BDKRB2蛋白筛选小分子抑制剂，发现化合物X可特异性阻断缓激肽信号传导，显著减轻遗传性血管水肿模型的病理症状，具有临床转化潜力。
---
如需真实文献，建议通过PubMed或Google Scholar搜索关键词：
`"BDKRB2 recombinant protein"` 或 `"B2 bradykinin receptor expression"`。
**Background of BDKRB2 Recombinant Protein**
The **Bradykinin Receptor B2 (BDKRB2)** is a G protein-coupled receptor (GPCR) that binds bradykinin, a potent inflammatory peptide involved in vasodilation, vascular permeability, and pain signaling. It plays a critical role in regulating cardiovascular homeostasis, inflammation, and nociception. The receptor is constitutively expressed in various tissues, including vascular endothelium, smooth muscle, and the nervous system.
**BDKRB2 recombinant protein** is engineered through molecular cloning techniques, typically expressed in mammalian systems (e.g., CHO or HEK293 cells) to ensure proper post-translational modifications and ligand-binding functionality. This recombinant form retains the receptor's native structure, including seven transmembrane domains and extracellular loops essential for bradykinin interaction. It is often tagged with markers (e.g., FLAG, His-tag) for purification and detection.
Research applications focus on elucidating BDKRB2's signaling mechanisms, which involve Gαq-mediated activation of phospholipase C, leading to IP3-dependent calcium release and nitric oxide production. Dysregulation of BDKRB2 is linked to hereditary angioedema, hypertension, sepsis, and chronic pain. The recombinant protein serves as a tool for drug discovery, screening antagonists or agonists, and studying receptor desensitization or internalization.
Notably, BDKRB2 polymorphisms (e.g., -9/+9 exon 1 variant) are associated with altered receptor expression and disease susceptibility. Recombinant variants mimicking these mutations help dissect their functional impacts. Overall, BDKRB2 recombinant protein is pivotal in advancing therapeutic strategies targeting inflammatory and cardiovascular disorders.
×
